Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Introduces a 92-protein Biomarker Panel

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Proseek® Multiplex Inflammation I 96x96 for inflammatory diseases.

Olink Bioscience has launched Proseek® Multiplex Inflammation I 96x96, a new protein biomarker panel that targets a wide range of inflammatory diseases. This panel complements the existing panels directed against Oncology and Cardiovascular diseases in a growing collection.

Proseek Multiplex Inflammation I 96x96 will be an important tool in the search for new multivariate protein expression patterns that could serve as biomarkers to improve prediction and prognosis of inflammatory diseases, as well as discovery of new drug targets.

Inflammatory mechanisms are involved in many types of diseases where the immune system creates a chronic inflammation often resulting in functional impairment of organs. Rheumatoid arthritis, multiple sclerosis, psoriasis, irritable bowel diseases, and asthma are examples of such diseases.

The inflammatory response also plays a major role in other diseases such as cardiovascular disorders, cancer, diabetes and Alzheimer’s disease. Chronic immune system disorders affect millions of people every year, and there is a great unmet need in predicting the efficacy of treatment options at individual level. It is crucial to find new biomarkers to meet these needs in personalized medicine but also for better healthcare in general through improving diagnostic and prognostic tools.

“With the launch of our next exciting multiplex immunoassay panel we are another step closer to the vision of identifying protein profiles that will change the way we prevent, diagnose and treat diseases. Proseek Multiplex makes anyone with access to biological material able to screen for protein biomarker profiles in an exceptionally efficient way.” says Andrea Ballagi, Chief Operating Officer at Olink Bioscience.

Proseek Multiplex Inflammation I 96x96 is a high throughput multiplex immunoassay that efficiently measures 92 inflammation-related proteins across 96 samples (including controls) simultaneously in only one microliter of serum or plasma. When used in combination with Fluidigm’s Biomark TM HD system, a high throughput real-time PCR platform, it enables researchers to analyze thousands of samples per week, which greatly accelerates the speed of discovery of new protein biomarkers.

“We are very pleased with the initial results obtained with Proseek Multiplex Inflammation I 96x96. We have already found several interesting biomarker candidates and we will now extend our study to compare the results with other available panels. Proseek Multiplex Inflammation I 96x96 is certainly a promising tool for future use in rheumatoid arthritis” say Professor Lars Klareskog and Assoc.Prof. Anca Catrina, Rheumatology clinic and research unit, Karolinska University Hospital and Karolinska Institutet.

The Proseek Multiplex Inflammation I 96x96 panel comprises established inflammatory markers as well as a few proteins with great potential to become new biomarkers for inflammatory disorders. The content of the panel has been designed in close collaboration with experts in various inflammatory disease fields such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, neuro inflammation, and respiratory diseases. The panel is therefore well suited to elucidating protein expression profiles in clinically relevant samples. Proseek Multiplex Inflammation I 96x96 is the third panel from Olink Bioscience.

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!